Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set a tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.

You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to seetings


News | Grünenthal PRO

News & Press Releases


February 15, 2020
Successful FDA inspection for Grünenthal’s manufacturing site in Italy: Our Italian site near Milan has become the second site in Grünenthal’s global manufacturing network to be successfully inspected by the FDA – following our production location in Switzerland. The site passed the inspection with zero findings. This excellent outcome confirms the outstanding quality level maturity and overall quality performance of the Grünenthal manufacturing network. The inspection focused on the biopharma assembly and packaging section of our Italian site. This success will provide the basis for expansion of Grünenthal’s contract manufacturing business.

October 2, 2019
Investing in powerful production: Grünenthal’s contract manufacturing customers are now benefitting from a huge upgrade of facilities at our Italian production site. This ambitious project was launched to transform the site into a centre of manufacturing innovation. Grünenthal Italy is now able to further expand the company’s biopharma assembly and packaging services. Read the full story on our global website: Our stories

February 9, 2019
New Medicines Verification System: Grünenthal now operates in line with new EU laws that protect patients by preventing counterfeit medicines from being dispensed in pharmacies. With the successful GoLive of one of the most complex programs in the last decade, we have made a decisive contribution to increasing patients’ safety. Read the full story on our global website: Read more

July 23, 2018
Grünenthal is setting a new standard in global demand and supply planning capabilities. We have just implemented a new IT solution, SAP Integrated Business Planning, to support the end-to-end IBP process and provide precise and adaptive planning possibilities, automation and seamless data integration. Another major step forward to strengthen our delivery reliability for our Contract Manufacturing Business customers.

June 29, 2018
Today our colleagues in Switzerland celebrate a major milestone: For 25 years they are producing Tramadol in Mitlödi for the global market – this is the world’s largest production unit for Tramadol Hydrochloride. We operate an API-production in top quality: well trained workforce, state of the art facility, precisely controlled processes and efficient Equipment.
Read more (Press release only available in German)

May 23, 2018
TECNANDINA, our Manufacturing Site in Ecuador, was honored from Novartis Ecuador with the annual award “Best Logistic Service Supplier in the Andean Cluster”.
Read more:

February 2018
Interview in World Pharmaceutical Frontiers


Santiago de Chile, Chile – January 12th, 2017: Grünenthal, an R&D-driven, privately owned international pharmaceutical company with headquarters in Germany, announced the introduction of its new women’s health products plant today. Grünenthal invested USD 14.5 million to build the 1,150 m2 hormone plant, which is the company’s center of excellence for hormone production and the most modern in Latin America.


Quito, Ecuador and Aachen, Germany. December 14, 2016. The Grünenthal Group announces today that its manufacturing site in Ecuador, Tecnandina, successfully passed the inspection to manufacture in accordance with the European GMP regulations. The certification covers the production of solid and semi-solid pharmaceuticals for the third time and now, for the first time, also liquid pharmaceuticals. This GMP Certificate will be valid for another three years.


Quito, Ecuador and Aachen, Germany. October 1, 2015. The Grünenthal Group announces that its Tecnandina manufacturing plant in Ecuador has received certification from the Regulatory Authority of Brazil, ANVISA (Agência Nacional de Vigilância Sanitária, Brazilian Health Surveillance Agency). This will allow Tecnandina to export pharmaceutical products also to Brazil and makes it the first production plant in Ecuador to receive ANVISA certification.